Literature DB >> 1676262

Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases.

T Ebisawa1, T Deguchi.   

Abstract

Genomic DNA clones coding for polymorphic and monomorphic arylamine N-acetyltransferases (NAT) of human liver were isolated from a genomic DNA library, and their restriction maps and partial nucleotide sequences were determined. Messenger RNA for monomorphic NAT was coded in one exon, while mRNA for polymorphic NAT was coded in two exons; the 5'-noncoding region was located in one exon 8 kb upstream from another exon containing the coding and 3'-noncoding regions. Recently, we have shown that there are three types of polymorphic NAT gene; one of the genes corresponds to a high NAT activity, while the other two genes give rise to a low NAT activity. The restriction fragment length polymorphism (RFLP) was analyzed by Southern blot hybridization of genomic DNAs from homozygotes of the three polymorphic NAT genes using various fragments of the cloned NAT gene. RFLPs of polymorphic NAT gene were observed in coding and 3'-flanking region upon digestion with BamHI and KpnI.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676262     DOI: 10.1016/0006-291x(91)90676-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Molecular genotyping of N-acetylation polymorphism to predict phenotype.

Authors:  M Mashimo; T Suzuki; M Abe; T Deguchi
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

Review 2.  A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review.

Authors:  Chunming Gong; Xueying Hu; Yong Gao; Yunfei Cao; Feng Gao; Zengnan Mo
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

3.  Study of NAT2 genetic polymorphism in West African subjects: example of an healthy non-smoker Senegalese population.

Authors:  A Touré; C Diop; M Cabral; M Fall; M Lhermitte; A Diouf; F Broly; D Allorge
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

4.  Chromosomal localization of human genes for arylamine N-acetyltransferase.

Authors:  D Hickman; A Risch; V Buckle; N K Spurr; S J Jeremiah; A McCarthy; E Sim
Journal:  Biochem J       Date:  1994-02-01       Impact factor: 3.857

5.  Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activities.

Authors:  Neville J Butcher; Ajanthy Arulpragasam; Hui Li Goh; Tamara Davey; Rodney F Minchin
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

6.  Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-02-07       Impact factor: 3.922

7.  Arylamine N-acetyltransferase activity in human cultured cell lines.

Authors:  E Coroneos; E Sim
Journal:  Biochem J       Date:  1993-09-01       Impact factor: 3.857

Review 8.  Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.

Authors:  Jason M Walraven; Yu Zang; John O Trent; David W Hein
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

9.  Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-06-25       Impact factor: 3.922

Review 10.  Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis.

Authors:  L M Bull; D L White; M Bray; Z Nurgalieva; H B El-Serag
Journal:  Dis Esophagus       Date:  2009-02-13       Impact factor: 3.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.